论文部分内容阅读
目的:观察分析不同降糖药物联合治疗老年糖尿病的临床疗效。方法:选取2014年12月至2015年12月在本院进行治疗的老年糖尿病患者100例作为本次研究对象,按照不同的治疗的方法随机将其分成对照组和实验组,每组50例;对照组予以二甲双胍联合格列美脲进行治疗,实验组予以罗格列酮联合瑞格列奈进行治疗;治疗结束后,对比分析两组患者的血糖指标、胰岛素功能指标和低血糖的发生情况。结果:实验组患者治疗后的血糖指标、胰岛素功能指标均明显优于对照组患者(P<0.05);而且实验组患者的低血糖发生率显著低于对照组患者(P<0.05);以上内容组间差异显著,具有统计学意义。结论:采用罗格列酮(胰岛素增敏剂)和瑞格列奈联合治疗老年糖尿病增强了人体内胰岛素的敏感性,促进胰岛素充分利用物质,对血糖指标也具有显著的改善作用,低血糖发生率低,值得临床用药推广。
Objective: To observe and analyze the clinical effects of different antidiabetic drugs in the treatment of senile diabetes mellitus. Methods: A total of 100 elderly patients with diabetes mellitus treated in our hospital from December 2014 to December 2015 were enrolled in this study. Patients were randomly divided into control group and experimental group with 50 cases in each group according to different treatment methods. The control group was treated with metformin combined with glimepiride. The experimental group was treated with rosiglitazone and repaglinide. After the treatment, the blood glucose, insulin function and hypoglycemia were compared between the two groups. Results: The blood sugar index and insulin function index of the experimental group were significantly better than those of the control group (P <0.05), and the incidence of hypoglycemia in the experimental group was significantly lower than that of the control group (P <0.05). The above contents Significant differences between groups, with statistical significance. CONCLUSIONS: The combination of rosiglitazone (insulin sensitizer) and repaglinide for senile diabetes increases insulin sensitivity in the human body and promotes the full utilization of insulin, with significant improvements in glycemic index and hypoglycaemia Low rate, it is worth to promote clinical use.